AR071309A1 - Metodos para tratar cancer y equipo con una combinacion que comprende un anticuerpo l2g7 humanizado y un agonista pten - Google Patents

Metodos para tratar cancer y equipo con una combinacion que comprende un anticuerpo l2g7 humanizado y un agonista pten

Info

Publication number
AR071309A1
AR071309A1 ARP090101264A ARP090101264A AR071309A1 AR 071309 A1 AR071309 A1 AR 071309A1 AR P090101264 A ARP090101264 A AR P090101264A AR P090101264 A ARP090101264 A AR P090101264A AR 071309 A1 AR071309 A1 AR 071309A1
Authority
AR
Argentina
Prior art keywords
humanized
antibody
equipment
methods
combination
Prior art date
Application number
ARP090101264A
Other languages
English (en)
Inventor
Yunqing Li
Roger Abounader
Original Assignee
Univ Virginia
Galaxy Biotech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia, Galaxy Biotech Llc filed Critical Univ Virginia
Publication of AR071309A1 publication Critical patent/AR071309A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Para tratamiento de cáncer se administra al paciente un inhibidor del Factor de Crecimiento de Hepatocito y un agonista de PTEN, proporcionándose un equipo comprendido por un anticuerpo L2G7 humanizado y un agonista PTEN seleccionado del grupo que consiste de rapamicinas, sirolimus y tensirolimus. Reivindicacion 12: El método de la reivindicacion 1, caracterizado porque el cáncer es glioma.
ARP090101264A 2008-04-11 2009-04-08 Metodos para tratar cancer y equipo con una combinacion que comprende un anticuerpo l2g7 humanizado y un agonista pten AR071309A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4444608P 2008-04-11 2008-04-11

Publications (1)

Publication Number Publication Date
AR071309A1 true AR071309A1 (es) 2010-06-09

Family

ID=41152336

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090101264A AR071309A1 (es) 2008-04-11 2009-04-08 Metodos para tratar cancer y equipo con una combinacion que comprende un anticuerpo l2g7 humanizado y un agonista pten

Country Status (7)

Country Link
US (1) US20110189169A1 (es)
AR (1) AR071309A1 (es)
CL (1) CL2009000844A1 (es)
PE (1) PE20091714A1 (es)
TW (1) TW200948380A (es)
UY (1) UY31756A1 (es)
WO (1) WO2009126842A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010119991A2 (en) 2009-04-17 2010-10-21 Takeda Pharmaceutical Company Limited Novel method of treating cancer
JP2013532627A (ja) * 2010-07-01 2013-08-19 武田薬品工業株式会社 ｃＭＥＴ阻害剤とＨＧＦおよび／またはｃＭＥＴに対する抗体との組み合わせ
WO2013036872A1 (en) * 2011-09-09 2013-03-14 Amgen Inc. Use of c-met protein for predicting the efficacy of anti-hepatocyte growth factor ("hgf") antibodies in esophageal and gastric cancer patients
US10143703B2 (en) 2014-01-02 2018-12-04 Massachusetts Eye And Ear Infirmary Treating ocular neovascularization
EP3490581A4 (en) * 2016-07-26 2020-10-14 Flagship Pioneering Innovations V, Inc. NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC PROCEDURES FOR TREATMENT OF CANCER
US11173325B2 (en) 2017-07-21 2021-11-16 Varian Medical Systems, Inc. Methods of use of ultra-high dose rate radiation and therapeutic agent
WO2020018904A1 (en) 2018-07-19 2020-01-23 Varian Medical Systems, Inc. Methods of use of ultra-high dose rate radiation and therapeutic agents
CA3148713A1 (en) 2019-08-12 2021-02-18 Interna Technologies B.V. New treatments involving mirna-193a
EP4110917A1 (en) 2020-02-28 2023-01-04 InteRNA Technologies B.V. Mirna-193a for promoting immunogenic cell death

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
CN103880955A (zh) * 2003-07-18 2014-06-25 安姆根有限公司 肝细胞生长因子的特异性结合物
US7202256B2 (en) * 2004-04-14 2007-04-10 Wyeth Proline CCI-779, production of and uses therefor, and two-step enzymatic synthesis of proline CCI-779 and CCI-779
GB0503962D0 (en) * 2005-02-25 2005-04-06 Kudos Pharm Ltd Compounds
CA2607699A1 (en) * 2005-06-02 2006-12-07 Galaxy Biotech, Llc Methods of treating brain tumors with antibodies
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
WO2008076278A2 (en) * 2006-12-13 2008-06-26 Schering Corporation Methods of cancer treatment with igf1r inhibitors

Also Published As

Publication number Publication date
UY31756A1 (es) 2009-09-30
PE20091714A1 (es) 2009-11-15
US20110189169A1 (en) 2011-08-04
TW200948380A (en) 2009-12-01
CL2009000844A1 (es) 2009-06-12
WO2009126842A1 (en) 2009-10-15

Similar Documents

Publication Publication Date Title
AR071309A1 (es) Metodos para tratar cancer y equipo con una combinacion que comprende un anticuerpo l2g7 humanizado y un agonista pten
UA99608C2 (en) PDGFRb-SPECIFIC INHIBITORS
MX361467B (es) Compuestos de isoindolina para uso en el tratamiento de cancer.
NI201000105A (es) Régimen de dosificación asociado con ésteres de paliperidona inyectables de acción prolongada.
UY32882A (es) (heteroarilmetil) tiohidantoínas sustituidas
MX2018015724A (es) Metodos de tratamiento de cancer de mama que expresa el receptor de androgenos (ar+).
AR083395A1 (es) Derivado peptidico nmu (neuromedina u) con elevado efecto anorectico
CL2012002037A1 (es) Uso de agonista doble del glucagon-glp-1 como agente inotropico en el tratamiento de la cardiopatía o la disfuncion cardiaca
MX2013012253A (es) Conjugados novedosos de aglutinante-farmaco (adc) y su uso.
BR112017006113A2 (pt) combinações sinérgicas de auristatina
CR10308A (es) Anticuerpos monoclonales humanizados para el factor de crecimiento del hepatocito
BR112014008819A2 (pt) métodos para o tratamento de síndrome de vazamento vascular e câncer
CU24349B1 (es) Composiciones que comprenden 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas útiles para el tratamiento del cáncer
AR092899A1 (es) Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion
UY33221A (es) MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA
BR112014009365A2 (pt) método para inibição da atividade de deubiquitinação
AR083205A1 (es) Metodo para tratar el crecimiento celular anomalo
CR20140075A (es) Métodos terapéuticos
CY1117438T1 (el) Μεθοδος για την προληψη και την θεραπευτικη αντιμετωπιση της σηψης
CL2012002858A1 (es) Combinación farmacéutica que comprende 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencilamidazol-2-il-quinolin-2-ona y al menos un inhibidor de mtor; método de tratamiento; y uso para el tratamiento y la prevención de una enfermedad proliferativa tal como cáncer de mama, tumores neuroendocrinos y linfonas, entre otras.
PE20130460A1 (es) Composiciones y metodos para el diagnostico y tratamiento de tumores
ECSP10010249A (es) Tratamiento de cardiopatías usando -bloqueantes
CR20110687A (es) Procedimientos de uso del factor liberador de corticotropina para el tratamiento de cancer
RU2013130449A (ru) Способ комбинированного лечения рака прямой кишки
MX2022016232A (es) Marcadores para uso en metodos para tratar canceres con conjugados de anticuerpo y farmaco (adc).

Legal Events

Date Code Title Description
FB Suspension of granting procedure